

# Index

- A**
- AADC (aryl aromatic decarboxylase), 319  
AAV. *See* Adeno-associated viruses (AAVs)  
AAVLife, 312  
Abbott Pharmaceuticals, 16  
*ABCD<sub>1</sub>* gene, 119  
ABO blood groups, 56  
Abortion, 28–29  
ACD (angiokeratoma corporis diffusum universale), 138  
Acid maltase, 142  
Acland, Gregory, 291  
ACT (Advanced Cell Technology), 295  
Actelion, 149  
Activase, 219  
Acute intermittent porphyria (AIP), 133  
ADA (adenosine deaminase deficiency), 116, 156  
Adams, Raymond D., 169, 288, 321–322  
Adeno-associated viral (AAV) vectors, 21, 284–293, 312, 337  
Adeno-associated viruses (AAVs), 159, 161–163, 179–180  
  AAV1, 289  
  AAV2, 165, 168, 285–286, 288  
  AAV8, 79  
  AAV9, 285  
  in gene therapy, 284–293  
  genome, 284  
  safety of, 285  
  serotypes, 285  
  structure, 284  
  tropism, 289  
Adenosine deaminase, 156  
Adenosine deaminase deficiency (ADA), 116, 156  
Adenovirus vector, 156, 158  
Advanced Cell Technology (ACT), 295  
Advocacy groups, 313. *See also specific groups*  
AFP ( $\alpha$ -fetoprotein), 24–25  
Aghion, Albert, 127–128  
AGTC, 292  
Aguirre, Gustavo, 291  
AHF (antihemophilia factor), 73, 74, 75, 78  
AIDS, 77–78  
AIP (acute intermittent porphyria), 133  
Aldurazyme, 19, 145, 147–148  
Alexion, 233, 310–311  
Alexis (Tsarevich of Russia), 69  
Alglucerase, 137. *See also* Cerezyme  
Alglucosidase  $\alpha$ , 145  
Ali, R.R., 166  
Alkaptonuria, 4–5  
Allan, William, 33  
Alnylam Pharmaceuticals, 297  
 $\alpha$ -fetoprotein (AFP), 24–25, 85  
 $\alpha$ -galactosidase, 145, 260  
 $\alpha$ -galactosyl hydrolase, 140  
 $\alpha$ -glucosidase, 142  
 $\alpha$ -iduronidase, 118, 144  
Altshuler, David, 333  
Alzheimer's disease, 259, 301, 317  
Ambroxol, 259  
American Association of Blood Banks, 57  
American Board of Genetic Counseling, 50  
American College of Medical Genetics, 49  
American College of Obstetricians and Gynecologists (ACOG), 304  
  on AFP screening, 24–25  
  Down syndrome testing standards, 85–86  
*American Journal of Human Genetics* (journal), 47–48  
American Medical Association (AMA), 49  
American Phage Group, 152  
American Red Cross, 57  
American Society of Gene and Cell Therapy (ASGCT), 161, 168, 180, 181  
American Society of Human Genetics (ASHG), 34, 40, 42, 46, 47, 48, 245  
Amicus Therapeutics, 260–261  
Amniocentesis, 81–88, 303, 305  
  Down syndrome and, 84–86  
  for gender identification, 82  
  karyotyping and, 83

## 372 Index

- Amniocentesis (*Continued*)  
  number performed annually, 86  
  risk of losing a pregnancy after undergoing, 84
- Amsterdam Molecular Therapeutics (AMT), 179, 289–290
- Amygdala, 201
- Amyotrophic lateral sclerosis, 293
- Andersen, Dorothy H., 267–270
- Anderson, W. French, 156
- Anderson, William, 138, 260
- Anderson–Fabry disease, 259
- Anemia Foundation, 61
- Anencephaly, 23, 28, 51
- Angiokeratoma corporis diffusum universale (ACD), 138
- Angiokeratomas, 138, 260
- Angiotensin II receptor blocker (ARB), 189
- Aniridia, 41–42
- Antibiotics, for cystic fibrosis, 267, 271–272
- Anticoagulant agents, 57
- Antihemophilia factor (AHF), 73–75, 78
- Antisense therapy, 195  
  Isis and, 206–207  
  for spinal muscular atrophy, 205, 207
- Aortic aneurysms, 187–190
- Aplastic anemia, 123
- Apolipoprotein E (APOE) gene, 317
- Apoxis, 243
- Arachnodactyly, 186
- ARB (angiotensin II receptor blocker), 189
- Arbaclofen, 201–202
- Arginase deficiency, 154
- Argininemia, 154
- Ariosa, 86
- Arrays, 324–325
- Aryl aromatic decarboxylase (AADC), 319
- Arylsulfatase A, 181
- Aryl-sulfate B, 111–112
- Ashkenazi Jews  
  Canavan disease, 287  
  Tay–Sachs disease, 89–90
- Asklepios BioPharmaceuticals, Inc., 163
- Aspartoacyclase (ASP), 287
- Astbury, W.T., 151
- Ataxia telangiectasia, 314
- Atenolol, 189–190
- Aubourg, Patrick, 171, 176–178
- Audentes, 292, 311
- Aurora Biosciences, 275–276
- Autism, 320–328  
  carnitine deficiency and, 327  
  definition of disorder, 322, 323  
  incidence of, 320, 323  
  knowledge of the genetic causes of, 323–328  
  trimethyllysine hydroxylase epsilon deficiency, 327–328
- Autism Speaks, 202
- Autism spectrum disorders (ASD), 202, 322–323, 326
- Autosomal dominant  
  brachydactyly type D, 281  
  Huntington's disease, 102
- Autosomal recessive  
  Canavan disease, 287  
  dystrophic epidermolysis bullosa, 209  
  Friedreich's ataxia, 190  
  sickle cell anemia, 39  
  spinal muscular atrophy (SMA), 204, 306–307
- Autosomes, 299, 330
- Avalanche, 292, 312
- Avascular necrosis, 66–67
- Avery, Oswald, 152
- AveXis, 312
- ### B
- Bacteria, genetically engineered, 218
- Bacterial inhibition assay, for PKU, 7, 10
- Bainbridge, J.W., 166
- Baltimore, David, 153
- Banding, chromosome, 83
- Barranger, John, 130, 257
- Batshaw, Mark, 158
- Batten disease, 149, 285–286
- Bauer, Wilhelm, 203
- Baxter Travenol (health products company), 132
- BBB. *See* Blood–brain barrier
- B cells, 114, 115–116, 160
- bcr-abl, 330
- Beall, Robert, 275, 313
- Bear, Mark, 201–202
- Bearn, Alex, 35
- Beaudet, Arthur, 326–328
- Becker, Andrew, 107
- Becker muscular dystrophy (BMD), 263, 266
- Beet, E.A., 39
- Bell, Julia, 196–197
- Bennett, Jean, 163, 166–168
- Benzer, Seymour, 153
- Berg, Paul, 154
- Berman, Brian, 136
- Berman, Robin, 135
- $\beta$ -globin gene, mutations in, 155
- $\beta$ -thalassemia, 59–64  
  bone marrow transplantation, 94, 114, 124  
  carrier testing, 82  
  David Weatherall and, 59–60  
  gene therapy, 155, 174, 175, 176, 178, 179, 182  
  iron overload, 310  
  life expectancy, 95  
  malaria and, 58, 60  
  mutations, 58, 60, 155  
  screening, 91, 93–96  
  transfusions for, 57, 94
- BGI, 97, 305–306
- Bianchi, Diana, 304
- Bianco, Ida, 37

- Bickel, Horst, 7–8  
Biggs, Rosemary, 74  
Bilirubin, 82  
Biobucks, 227  
Biochemical screening, for Down syndrome, 85–87  
Biogen Idec, 79, 207  
BioMarin, 19–21, 144–145, 266, 311  
Biomarkers, 337  
Birth defects, surgical treatments for, 242–243  
Bjornsson, Hans, 302  
Blair, Henry, 132  
Blastomere cell, 99  
Blombäck, Birger, 74  
Blombäck, Margareta, 74  
Blood bank, 57, 122–123  
Blood–brain barrier (BBB), 146–147, 172, 255–256  
Blood coagulation, 69. *See also* Hemophilia  
Blood transfusions, 37–38  
    frequency in United States, 57  
    for hemophilia, 70, 72  
    history of, 55–57  
    for sickle cell anemia, 67  
    for thalassemia, 57, 60–64, 94  
Blood type, 56  
Bluebird bio, 178–179, 182, 228  
Blundell, James, 56  
BMD (Becker muscular dystrophy), 263, 266  
BMT. *See* Bone marrow transplant  
Bone marrow  
    destruction in Gaucher disease, 135  
    gene therapy and, 156, 160  
    hematopoietic stem cells, 107  
    radiation sickness and, 108  
    viral transduction of, 155, 175  
Bone marrow donor registry, 113–114  
Bone marrow transplant (BMT), 110–120  
    for  $\beta$ -thalassemia, 94, 114, 124  
    for childhood cerebral adrenoleukodystrophy (CCALD), 119–120, 171–173, 178, 179  
    chimera creation, 112  
    hematopoietic stem cells, 107  
    history of, 108–109  
    for Hurler syndrome, 118–119  
    for immune deficiency disorders, 110, 114–117  
    for leukemia, 108–109, 110–111  
    for lysosomal storage disorders, 117–119  
    for rDEB, 224  
    risk of, 94  
    for storage diseases, 111–112  
    T-cell depletion, 116, 117  
    for thalassemia, 38  
    for X-linked severe combined immune deficiency (X-SCID), 159  
Bowman, Jim, 92  
Boyse, Edward A., 120–121  
Brachydactyly type D, 281  
Brady, Roscoe, 128–132, 134, 135, 140, 257  
*BRAF* gene, 311, 331  
Brain  
    blood–brain barrier, 146–147, 172, 255–256  
    drug delivery to, 146–148  
Brain cutting, 288, 321  
*Brave New World* (Huxley), 58  
Breg, Jr., W. Roy, 83  
Brill, N.E., 257  
Brin, Sergey, 319  
Brown, Michael, 47  
Broxmeyer, Hal, 121  
Bruckner-Tuderman, Leena, 224  
Bubble boy syndrome, 110  
Buck, Pearl S., 12–13  
Bush, George W., 98, 294  
  
C  
C-1 esterase inhibitor, FDA approval, 309  
*Caenorhabditis elegans*, 296  
CAG repeats, 102, 199  
Cambrooke Therapeutics, 17  
Canavan, James F., 287  
Canavan, Myrtelle Moore, 287–288  
Canavan disease, 285, 287–289  
Cancer  
    chronic myelogenous leukemia, 330–331  
    colon, 329  
    DNA sequencing, 329  
    gene therapy trials and, 160–161, 175  
    genetic counseling, 53  
    melanoma, metastatic, 331, 333  
    monogenic cancer syndrome, 43  
    mutations, 311  
    personalized medicine and, 53  
    prize of mutation-specific drugs, 333–334  
    SV40 virus and, 153  
    tumor profiling, 331–332  
Cantor, Harvey, 120  
Cao, Antonio, 94–96, 97  
Capsids, 337  
Cardiomyopathies, 332  
Carlsson, Arvid, 318  
Carnitine, 327–328  
Carpenter, Randall, 201  
Carrier testing, 82, 89–98  
     $\beta$ -thalassemia, 91, 93–96  
    cystic fibrosis, 96  
    direct to consumer DNA-based, 97  
    DNA sequencing, 96–97  
    “Jewish panel,” 90  
    sickle cell anemia, 91–94  
    Tay–Sachs disease, 89–91  
Cartier, Nathalie, 176, 178  
Casal, Magi, 240–242, 245–246  
Caspersson, Torbjörn, 48, 83  
“Catalogs of Autosomal Dominant, Autosomal Recessive, and X-Linked Phenotypes,” 45  
Cavazzana-Calvo, Marina, 159–160  
CBP protein, 282

374 *Index*

- CCALD. *See* Childhood cerebral adrenoleukodystrophy
- CCR5 receptor, 298
- CD34, 298
- Celiac syndrome, 268–269
- Cell, coining of word, 105
- Cell biology, history of, 105–107
- Cell Genesis, 180
- The Cell in Development and Heredity* (Wilson), 107
- Center for Drug Evaluation and Research (CDER), 310
- Central dogma of molecular biology, 296
- Cerdelga, 150
- Cereals, folate in, 26–28
- Ceredase, 135–138
- Cerezyme (imiglucerase), 137–138, 146
- CFF (Cystic Fibrosis Foundation), 96, 271, 275, 277–279, 313
- CFTR* gene, 275
- Chaperones, 256–261
- Chaperone therapy
- Fabry disease, 259–261
  - Gaucher disease, 259
- Chaperonopathies, 259
- Charcot, Jean-Martin, 317
- Charcot–Marie–Tooth disease, 283
- Chelating agents, 61–63, 95, 310
- Chen, Mei, 215–216, 219–220, 223
- Childhood cerebral adrenoleukodystrophy (CCALD), 119–120, 123
- gene therapy, 174–179
  - stem cell transplantation, 171–173
- Children’s Bureau, 11
- Children’s Hospital in Philadelphia (CHOP), 291, 292, 311
- Childs, Barton, 35
- “The Child Who Never Grew” (Buck), 13
- Chile, folate fortification policy, 27
- Chimeras, 3, 112, 115
- Chinese hamster, as research animal, 217
- Chinese hamster ovary (CHO) cells, 216–220
- Chiriboga, Claudia, 207
- Chloride ions, transport of, 274–276
- Chloride transmembrane function regulator (CTFR), 277, 279–280
- Chorea, 101
- Chorionic villus sampling, 85
- Christ, Josef, 236
- Christ–Siemens–Touraine syndrome, 236
- Chromatin, 302
- Chromosomal microarray analysis, 303–304
- Chromosome banding, 83, 324, 325
- Chronic myelogenous leukemia, 330–331
- Chu, T.C., 48
- Church, George, 298
- Ciba-Geigy, 62, 330
- Clarke, Angus, 237
- Cleavage stage biopsy, 99
- Clegg, John, 59
- Cline, Martin, 155
- Clinical trials, 312
- Clinicaltrials.gov (website), 67
- Clotting, 69, 79. *See also* Hemophilia
- Clotting factors. *See* Factor VIII
- Cloud, Richard, 229–232
- Clustered regularly interspersed short palindromic repeat (CRISPR) elements, 297, 298, 336, 337
- Coagulation, 75
- Coagulation factors, FDA approval of, 309–310
- Coenraads, Monica, 313, 315
- Cofactor, 19, 25
- Coga, Arthur, 55
- Cognitive development
- Hurler syndrome and, 119
  - of persons with PKU, 18
- Cognitive Genomes Project, 306
- Collagen VII, 211, 216, 219–220, 222–228
- Collins, Francis, 274
- Colon cancer, 329
- ColVIIA* gene, 219
- The Coming of the Golden Age* (Stent), 151
- Committee for Advanced Technologies, 290
- Concanavalin A, 130
- Congenital muscular dystrophy (CMD), 231
- Congenital stationary night blindness, 164–165
- Connective tissue disorders, 44
- Cooley, Thomas Benton, 36, 59, 60
- Cord blood, 120–125, 171, 173
- Cord Blood Registry, 122
- Correctors, cystic fibrosis, 275, 279
- Cost of care, 333–335
- Creutzfeldt–Jakob disease, 136
- Crick, Francis, 48, 49, 152, 276
- CRISPR. *See* Clustered regularly interspersed short palindromic repeat (CRISPR) elements
- Crooke, Stanley, 206
- Cross correction, 181
- Crow, James, 35
- Crowley, John, 314
- Cryoprecipitate, 75–76
- Crystal, Ron, 285–286, 288
- CTFR (chloride transmembrane function regulator), 277, 279–280
- CureCMD, 228
- Cyclosporine, 117
- Cystagon, 149
- Cysteamine, 149
- Cystic fibrosis, 267–280
- carrier testing, 96
  - cloning of gene, 274–275
  - early history of, 267–272
  - gene therapy, 156
  - immunoreactive trypsinogen test (IRT), 270–271
  - incidence/prevalence of, 267
  - Kalydeco, 267, 277–279, 310, 334–335
  - life expectancy, 267, 271–272
  - lung transplants, 273–274
  - mutations, 274–280

research funding, 275  
specialty clinics, 271–272  
sweat test, 270–271  
Cystic Fibrosis Foundation (CFF), 96, 271, 275,  
277–279, 313  
Cystinuria, 5  
Cytogenetics, 42, 83, 324, 330  
Cytotrophoblasts, 305

## D

Dacarbazine, 331, 333  
*Daedalus* (Haldane), 58  
Dalton, Joseph, 247  
Darwin, Charles, 106, 326  
Data Safety Monitoring Board, 252  
Dausset, Jean, 109  
Davenport, Charles, 32  
Deafness, hereditary, 282–283  
deCODE genetics, 333  
de Duve, Christian, 128  
Deep brain stimulation (DBS), 318  
Delbrück, Max, 152, 153  
Dermatan sulfate, 111–112  
Desnick, Robert, 137, 140  
de Souza, Mark, 215, 220–224, 227  
Diabetes, 333  
Dice, Lee, 33, 36, 40  
Dietary therapy  
  applications of, 22  
  for neural tube defects, 25–29  
  for PKU, 8–9, 11, 15–19  
Dietz, Hal, 188–190  
Dight Institute for Human Genetics at the  
  University of Minnesota, 40  
Dilated cardiomyopathy, 332  
Dimension Therapeutics, 292  
di Sant'Agnesse, Paul, 270  
DMD. *See* Duchenne muscular dystrophy  
DNA  
  as the hereditary material, 152  
  structure of, 152  
  variation in, 316  
DNA repair systems, 297  
DNA sequencing  
  for cardiomyopathies, 332  
  cost of, 96  
  discovery of causative mutations, 332  
  fetal, 303–307  
  mitochondrial genome, 283–284  
  power of advances in, 282–284  
  for screening, 96–97  
  on tissue removed from a cancer, 329  
  tumor profiling, 331–332  
  whole exome, 283, 325  
  whole genome sequencing, 305–306,  
  314  
DNA testing. *See also* Genetic testing  
  for cystic fibrosis, 271, 274  
  future of, 339  
Dolichostenomelia, 186  
Dolly, the sheep, 293

Dominant disorder  
  aniridia, 41–42  
  Marfan syndrome, 44  
Donor registry, bone marrow, 113–114  
Donors  
  bone marrow, 109–116, 125  
  cord blood, 121–123  
  lung transplant, 273–274  
Dopamine, 318–319  
Double blind study, 140–141  
Doudna, Jennifer, 298  
Down, John Langdon, 299  
Down syndrome, 48, 299–302  
  amniocentesis and, 82, 84–86  
  clinical features of, 300–301  
  emerging therapies, 301–302  
  genetic testing, 51–52  
  increase of, 84, 86  
  MAT<sub>21</sub> test, 86–87  
  maternal age and, 303, 304  
  mouse model for, 301  
  PAPA test, 85  
  pregnancy termination and, 84–86  
  preimplantation genetic diagnosis (PGD),  
  98  
  prenatal screening, 303–305  
  risk increase with maternal, 84  
  triple test for, 85  
  ultrasound screening, 85  
Down Syndrome Congress, 301  
Doxycycline, 189  
Drisapersen, 266  
Drug development. *See also specific disorders;*  
  *specific drug*  
  advocacy groups and, 313  
  approval by regulatory agencies, 309–310  
  clinical trials, 312  
  family groups and, 314–315  
  new gene therapy companies, 311–312  
  orphan drug status, FDA, 312–313  
  streamlining regulatory pathways, 338  
  valuation of orphan disease companies,  
  310–311  
Druggable genome, 184  
Drugs  
  genetically engineered, 127–150  
  Orphan Drug Act, 132–133  
Druker, Brian, 330–331  
Duchenne de Boulogne, Guillaume,  
  261–262  
Duchenne muscular dystrophy (DMD),  
  83, 184, 228, 310  
  clinical features of, 262–263  
  exon skipping, 264–266  
  history of, 261–263  
  incidence of, 262  
  life expectancy, 263  
Duke University Medical Center,  
  transplantations and, 112, 123  
Dulbecco, Renato, 153  
Dwarfism, 45

## 376 Index

- Dystrophic epidermolysis bullosa, recessive (rDEB)  
animal models, 220, 224–225  
drug delivery, 222–223  
funding proposal for protein replacement therapy, 220–228  
Hibbard family experience with, 210–214, 222, 225–226  
history of, 209–210  
incidence of, 215, 221–222  
mutation in, 211  
Dystrophin, 184, 229, 263, 265, 310  
*Dystrophin* gene, 263–264
- E**
- ECM (extracellular matrix), 219  
Ectodermal dysplasias, 237  
Ectodysplasin A (EDA) protein, 239, 246–247  
*EDA1* gene, 238, 241  
EDA1 protein, 242–243, 246  
EDA receptor (EDAR), 247, 252  
EDL200, 247, 249, 251, 253–254  
Edimer Biotech S. A., 243  
Edimer Pharmaceuticals, 247–254  
Edison Pharmaceuticals, 195  
Edward (Duke of Kent), 68  
Egeland, Borgny, 6–7, 11, 18  
Ehrlich, Henry, 99  
Elaprase (idursulfase), 147  
Eliglustat, 150  
Eloctate, 79  
EMA. *See* European Medicines Agency  
Embryonic stem (ES) cells, 294–295  
Embryos  
cells from human, 294  
disposition of, 100  
PGD and, 99  
Emerging therapies, 281–307  
AAV gene therapy, 284–293  
Down syndrome, 299–302  
fetal sequencing, 303–307  
gene editing, 297–298  
induced pluripotent stem cells, 293–295  
RNAi, 296–297  
Endogamy, 90  
Endoplasmic reticulum (ER), 258–259  
Enobia, 311  
Ensure, 16  
Enzyme replacement therapy (ERT),  
127–148  
cost of drugs, 138, 146, 148  
delivery to brain, 146–148  
drug approval, FDA, 309  
Fabry disease, 138–141, 145  
Gaucher disease, 127–138, 257–258  
Hurler syndrome, 144–145  
Pompe disease, 141–144, 146  
Enzymes  
deglycosylation, 130–131  
from human placentas, 129–130  
misfolded, 258–259  
Epidermal growth factor, 240  
Epigenetics, 302  
Episome, 161  
ER (endoplasmic reticulum), 258–259  
Erb, William, 203–204  
ERT. *See* Enzyme replacement therapy  
Erythropoietin, 195  
ES (embryonic stem) cells, 294–295  
*Escherichia coli*, 218  
Estriol, 85  
Eteplirsen, 264–265  
Ethics, genetic engineering, 154  
Eugenics, 31–33, 35, 46, 92, 210, 236, 338  
Eugenics Record Office, 32, 35  
Eugenics Society of Canada, 46  
Eunice Kennedy Shriver Center for Mental Retardation (Waltham, Massachusetts),  
14, 169, 321  
European Medicines Agency (EMA), 141, 179,  
289  
Evolution, conservative nature of, 301  
Exon-skipping, 264–266, 310  
Exter, Neil, 224, 227  
Extracellular matrix (ECM), 219  
Eye disease, gene therapy for, 163–169
- F**
- F508 mutation, in cystic fibrosis, 278, 279  
Fabrazyme, 145, 260  
Fabry, Johannes, 138, 260  
Fabry disease, 129–130, 138–141, 145, 146  
chaperone therapy, 259–261  
history of, 259–260  
life expectancy, 260  
Fabry Outcome Study (FOS), 140  
Factor IX, 79, 162, 291  
Factor VIII, 69–70, 75–76, 78–79, 132, 335  
Family groups, influence of, 314–315  
Family history, 329  
Fanconi, Guido, 121  
Fanconi anemia, 121  
*Fantasia* (film), 151  
Fantus, Bernard, 57  
Farber, Sidney, 108  
Fardeau, M., 229  
Favism, 2–3  
FDA. *See* Food and Drug Administration  
Fermentation system, nonhuman cells as a,  
137  
Fernald State School, 1, 14, 198, 288  
Ferroxipone, 310  
Fetal cell analysis, 87  
Fetal chromosome analysis, 84–86  
Fetal sequencing, 303–307  
FFP (fresh frozen plasma), for hemophilia,  
70–71, 74–75  
Fibrillin, 188–190  
Fidelity Biosciences, 311  
Finer, Mitch, 177  
Firazyr, 310  
Fire, Andrew, 296

Firebird Foundation, 74  
Fischer, Alain, 116, 159  
FMR1 protein, 199–200  
Folate, 25–29, 53  
Følling, Asbjørn, 6–7, 9, 11, 13, 14  
Food, fortification of, 26–29  
Food and Drug Administration (FDA), 309  
    bluebird bio gene therapy trials and,  
    178–179  
    Cerdelga (eliglustat) approval, 150  
    Ceredase and, 135–136  
    Chinese hamster ovary cells as GRAS,  
    219  
    Complete Response Letter from, 149  
    cystic fibrosis drugs and, 267, 278, 280  
    drisapersen and, 266  
    Eloctate approval, 79  
    exon-skipping technology and, 265–266  
    expense of drug approval, 168–169  
    folate fortification, 26  
    future of drug approval, 337  
    gene therapy and, 157  
    Glybera and, 290  
    Investigational New Drug application,  
    254  
    Kalydeco approval, 267  
    Kuvan approval by, 20  
    medical foods, 16  
    miglustat approval, 149  
    mucopolysaccharidosis and, 145–146  
    Niemann–Pick C (NP-C) disease and,  
    149  
    orphan drug status, 133, 312–313  
    Pompe disease and, 143  
    rColVII and, 227–228  
    toxicology studies in animals, 166  
    XLHED therapy and, 251, 254  
    Zelboraf approval, 331  
Fordyce, Jim, 215, 220–221, 223–224  
Fortification, of foods with folate, 26–29  
Foundation Medicine, 53  
*Foundations of Genetics, Racial Hygiene and  
Population Policy* (Siemens), 236  
Fox, Michael J., 318  
Fragile X syndrome, 88, 185, 196–203, 324  
    animal models, 200–201  
    history of, 196–198  
    incidence of, 198  
    test for, 199  
    therapy, 201–202  
Fraser, Clarke, 35  
Frataxin, 184, 190–191, 193–196  
Fred Hutchinson Cancer Research, 113  
Freire-Maia, Newton, 237  
Fresh frozen plasma (FFP), for hemophilia,  
    70–71, 74–75  
Friedman, Theodore, 153, 156, 157  
Friedreich, Nikolaus, 190  
Friedreich's ataxia, 184, 190–196  
FSH, 197  
Fusion protein, 241–242, 333  
Future challenges, 335–340

## G

G6PD deficiency, 2–3, 281  
G551D mutation, in cystic fibrosis, 277–279  
GAA triplet, 193  
GAGs (glycosaminoglycans), 145, 148  
Gaide, Olivier, 241  
Gain-of-function diseases, 296  
Galactocerebroside, 129  
Galactosemia, 22  
Galton, Francis, 31  
 $\gamma$ c subunit, 159–160  
 $\gamma$ -aminobutyric acid type B (GABA-B), 201  
Gangliosides, 89  
Gao, Guangping, 161, 285, 286–289  
Gargoylism, 144  
Garrod, Archibald, 4–6, 21, 31  
Gastrointestinal disease, cystic fibrosis  
    as, 267–269  
Gates, Sr., William, 275  
Gates Foundation, 275  
Gaucher, Philippe Charles Ernest, 127, 256  
Gaucher cells, 127  
Gaucher disease, 127–138, 146–149, 310  
    chaperone therapy, 259  
    clinical forms of, 257  
    cost of therapy, 258  
    eliglustat for, 150  
    enzyme replacement therapy, 257–258  
    history of, 256–257  
    substrate reduction therapy (SRT) to treat,  
    149  
Geismar, Ruth and Keith, 244  
Gelsinger, Jesse, 157–159  
Gender identification, by amniocentesis, 82–83  
Gene, mutation frequency of, 41  
Gene arrays, 324–325  
Gene dosage effect, 300  
Gene editing, 297–298  
Gene mapping, 45, 101–102  
Genentech, 132  
Gene pool, 41  
Generally regarded as safe (GRAS), 219  
Gene silencing, 199, 296, 302  
Gene targeting, 298  
Gene therapy, 151–182  
    adeno-associated viral (AAV), 161–162,  
    284–293, 312  
    adenosine deaminase deficiency, 156  
    autologous, 176–177  
     $\beta$ -thalassemia, 156, 174, 175, 176, 178, 179,  
    182  
    Canavan disease, 288–289  
    challenges in, 291–292  
    childhood cerebral adrenoleukodystrophy  
    (CCALD), 174–179  
    clinical trials, 312  
    coming of age of, 159–163  
    cystic fibrosis, 275  
    drug approval, 310  
    duration of positive therapeutic effect, 167  
    Friedreich's ataxia, 196

378 *Index*

- Gene therapy (*Continued*)  
funding of companies, 292  
future of, 336–337  
hemophilia, 79, 162–163, 291  
history of, 155–159  
investment in, 180  
Leber congenital amaurosis, 163–169, 291  
Lesch–Nyhan syndrome, 156  
LINCL, 286  
lipoprotein lipase deficiency, 179–180,  
289–290  
metachromatic leukodystrophy, 181–182  
moratorium on trials, 159  
new companies, 311–312  
origins of, 153  
ornithine transcarbamylase deficiency  
(OTC), 157–158  
Parkinson disease, 318, 319, 320  
PKU, 21  
preventive, 181  
rDEB, 224  
sickle cell anemia, 174–175  
spinal muscular atrophy, 205  
venture capital and, 163  
X-linked adrenoleukodystrophy, 169–179  
X-linked severe combined immune  
deficiency (X-SCID), 159–161, 175  
Genetically engineered drugs, 127–150, 218  
Genetic counseling, 40, 49–53  
impact of, 51–52  
National Genetic Diseases Act  
and, 98  
training in, 49–50  
Genetic diseases  
number of disorders, 183  
number of treatable monogenic disorders,  
183–184  
Genetic engineering, birth of, 154  
Genetic Information Nondiscrimination Act  
(GINA), 98  
Genetics Institute, 132  
Genetics Society of America, 42  
Genetic testing, 81–103  
amniocentesis, 81–88  
 $\beta$ -thalassemia, 91, 93–96  
carrier testing, 82, 89–98  
chromosomal microarray analysis,  
303–304  
direct to consumer, 319  
ethical dilemmas raised by, 81, 102  
fetal screening, 303–307  
Huntington's disease, 100–103  
number of diseases tested for, 51  
preimplantation, 98–103, 339  
revenue from, 51  
sickle cell anemia, 91–94  
social policy questions, 98  
Tay–Sachs disease, 89–91  
Genetic testing companies, 51  
Genetix Pharmaceuticals, 156,  
174–177  
Genistein, 150  
Genome sequencing  
cost of, 96  
for screening, 96–97  
Genome-wide association studies, 316  
*Genomics* (journal), 46  
Genzyme, 51, 255, 292  
eliglustat, 150  
Fabry disease and, 140–141, 260  
Gaucher disease and, 131–132, 134–138,  
150, 258  
growth of, 145–146  
Pompe disease and, 141–144  
revenue, 138, 144, 148  
Sanofi acquisition of, 146  
Gerard, Ralph Waldo, 75  
Germ theory, 4  
Gilster, John, 239  
GINA (Genetic Information Nondiscrimination  
Act), 98  
Glass, H. Bentley, 35, 43  
GlaxoSmithKline, 180, 181, 261, 266  
Gleevec, 330–331, 333  
Global Blood Therapeutics, 67  
Globotriaosylceramide (GL-3), 141, 260–261  
Gluckman, Eliane, 121  
Glucocerebrosidase, 129–132, 134–135, 136,  
257, 259  
Glucose-6-phosphate dehydrogenase (G6PD)  
deficiency, 2–3, 281  
Glutathione, 3  
Glybera, 179–180, 290, 310  
Glycogen, 141  
Glycogen storage disorder, Pompe disease as,  
141–144  
Glycosaminoglycans (GAGs), 145, 148  
Glyko, 145  
Goldstein, Joseph, 47  
Good, Robert, 109–110  
*The Good Earth* (Buck), 13  
Gowers, William Richard, 262  
Gowers sign, 262  
Grace Wilsey Foundation (GWF), 314–315  
Graft *versus* host disease (GVHD), 111, 116–119,  
172  
GRAS (generally regarded as safe), 219  
Graves, Charles, 237  
Graves, Laura, 113  
Gurdon, John B., 293  
Gusella, James, 101–102  
Guthrie, Robert, 10–11, 14, 21, 22  
GVHD (graft *versus* host disease), 111, 116–119,  
172  
GWF (Grace Wilsey Foundation), 314–315
- H**
- Hacein-Bey-Abina, Salima, 160  
HAE (hereditary angioedema), 309–310  
Haeckel, Ernst, 106–107  
Hair growth, XHLED and, 235–240,  
252



- Haldane, J.B.S., 58  
Hallopeau, François Henri, 209  
Hallopeau-Siemens syndrome, 210  
Handyside, Alan, 99  
Harper, Margaret, 268, 272  
Harvey, A. McGehee, 44  
Harvey, William, 55  
Hatch, Orrin, 133  
HCG (human chronic gonadotropin), 85  
HDAC inhibitors, 195  
Health insurance coverage, 98  
Heart disease, 44  
    cardiomyopathies, 332  
    gene variants protective against, 333  
Hecht, Fred, 198, 324  
Helper T cells, 120  
Hematopoietic stem cells, 107  
Hemoglobin, 39–40  
    fetal, 65, 67  
    in Gaucher disease, 131  
    gene therapy and, 155, 174–176, 182  
    in sickle cell disease, 91  
    thalassemia and, 58, 59–63, 94  
    transfusion reaction and, 56  
Hemoglobin electrophoresis, 93  
Hemophilia, 56, 68–80  
    amniocentesis for gender identification, 82  
    cost of treatment, 76, 335  
    Eloctate, 79  
    Factor VIII, 69–70, 75–76, 78–79, 132  
    FDA approval of therapies, 309  
    gene therapy, 79, 162–163, 291  
    history, 68–78  
    HIV infection and, 77–78  
    incidence of, 79–80  
    life expectancy, 77, 78  
    Robert and Suzanne Massie, 71–74  
    therapies for, 70–76  
    treatment centers, 78  
    variations in severity, 69–70  
Hemophilia A, 68, 79, 82  
Hemophilia B, 79, 162–163, 291  
Hepatitis C, 77  
Hereditary angioedema (HAE), 309–310  
Hereditary deafness, 282–283  
*Hereditary Genius* (Galton), 31  
*Hereditary in Relation to Eugenics* (Davenport), 32  
Heredity clinics, 36, 40, 48  
*Heritable Disorders of Connective Tissue* (McKusick), 44  
Herrick, J.B., 38  
Herrick, Richard, 108  
Hershey, Alfred, 152  
HES (hypereosinophilic syndrome), 331  
Hexosaminidase A, 89  
HFEA (Human Fertilization and Embryology Authority), 100  
Hibbard, Bryan, 25  
Hibbard family, DEB and, 210–214, 222, 225–226  
High, Katherine, 79, 162, 163, 169, 292  
Hippocampus, 302  
Hirschhorn, Kurt, 35  
Histocompatibility antigens, 109  
Histone proteins, 302  
HIV (human immunodeficiency virus), 77–78, 285, 298  
HLAs. *See* Human leukocyte antigens  
Hodges, Brad, 229–233  
Hoffmann, Johann, 203–204  
Holmes, Oliver Wendell, 293  
Homogentisic acid, 4  
Hooke, Robert, 105  
Hopkins, Frederick, 4  
*HOXD1* gene, 281  
HUGO, 46  
Human chronic gonadotropin (HCG), 85  
Human Fertilization and Embryology Authority (HFEA), 100  
Human Genome Project, 3, 45, 48  
Human immunodeficiency virus (HIV), 77–78, 285, 298  
Human leukocyte antigens (HLAs), 109–110, 113, 115–116, 118–124, 121  
Hungerford, David, 333  
Hunter syndrome, 147  
Huntington, George, 100–103  
Huntington protein, 102  
Huntington's disease, 100–103, 200  
Hurler syndrome, 19, 118–119, 123, 144–145, 147  
Huttner, Kenneth, 249–250  
Huxley, Aldous, 58  
Hydroxyurea, 67, 206  
Hypereosinophilic syndrome (HES), 331  
Hyperthermia, XLHED and, 237, 238  
Hypertrophic cardiomyopathy, 332  
Hypohidrotic ectodermal dysplasia, 245. *See also* X-linked hypohidrotic ectodermal dysplasia (XLHED)  
Hypophosphatasia, X-linked, 311
- I**
- Idebenone, 194–195  
Identical twins, transplants and, 108–109  
Imatinib, 330–331  
Imiglucerase (Cerezyme), 137–138, 146  
Iminosugars, 148  
Immigration laws, 32  
Immune deficiency disorders, 110, 114–117  
Immunoglobulin G (IGG), 135  
Immunoreactive trypsinogen test (IRT), 270–271  
Immunosuppressive drugs, 125  
Inborn errors of metabolism, 2, 4–6, 7, 19, 22, 31  
Incidence, 230–231  
Individualized medicine, 311  
Induced pluripotent stem cells (iPSCs), 294–295  
Ingram, Vernon, 39

**380**      *Index*

Insertional mutagenesis, 161  
Institutional Review Board (IRB), 157–158  
Insulin, 129  
Insurance discrimination, 98  
Intelligence, gene variation and, 306  
Interleukins, 159  
International Ectodermal Dysplasias Patient Registry, 250  
International Gaucher Registry, 148  
International Rare Disease Day, 225  
Intrathecal delivery of enzyme, 147  
Intravenous drug delivery, 222–223  
Introns, 264  
Investigational New Drug application, 251  
In vitro fertilization, preimplantation genetic diagnosis and, 98–100, 103  
Iodine, 26  
IPSCs (induced pluripotent stem cells), 294–295  
IRB (Institutional Review Board), 157–158  
Iron  
    chelating agents, 194  
    faulty metabolism in Friedreich's ataxia, 191, 194  
    overload, 61–62, 94  
Irons, Ernest Edward, 38  
IRT (immunoreactive trypsinogen test), 270–271  
Isis Pharmaceuticals, 195, 206–207  
Isofagomine tartrate, 260

**J**

Jacob, François, 153  
Javits, Jacob, 98  
Johnson, Nick, 191–193  
Johnson, Ramsay, 249–250  
Johnson & Johnson, 133  
*Journey* (Massie), 71, 74

**K**

Kaback, Michael, 89–90, 94  
Kabuki syndrome, 302  
Kakkis, Emil, 144–145, 147–148, 311  
Kalydeco, 267, 277–279, 310, 334–335  
Kan, Y.W., 94–95  
Kanner, Leo, 322  
Karyotyping, 83–86, 303–305  
Karyotype, 330  
Kelley, Laureen, 68  
Kennedy, John F., 13–14  
Kennedy, Ted, 14, 74, 92, 98, 133  
Kennedy-Krieger Institute, 169  
Kessler, David, 26  
Key opinion leaders, 177  
Kidney transplantation, 108, 109  
Killer T cells, 120  
Kirby, Neil, 246, 248–249  
Knockout mice  
    development of, 217, 220  
    Fabry disease and, 140

    for lipoprotein lipase deficiency, 290  
    model of Canavan disease, 289  
    for rDEB, 220  
    RPE65 gene, 165  
Knudson, Alfred, 35  
Koeppen, Arnulf, 196  
Kohrt, Holbrook, 78  
Krivit, William, 110–112, 118, 171  
Kunkel, Lou, 263  
Kuvan, 20–21

**L**

Lambda bacteriophage, 154  
Laminin-111, 229–230, 233  
Laminin-211, 231  
Laminin M, 229  
Landsteiner, Karl, 56  
Laronidase, 145, 147  
Lasker Award, 318, 331  
Lasker Foundation, 218  
Late-infantile neuronal ceroid lipofuscinosis (LINCL), 286  
Laughlin, Harry Hamilton, 32  
Lawrence, Jeanne, 302  
L-dopa, 318  
Leber, Theodor, 164  
Leber congenital amaurosis (LCA), 163–169, 291  
Leboulch, Philippe, 174  
Lejeune, Jérôme, 48, 88, 300  
Lentiviral vectors, 67, 174–176, 179, 181, 285  
Leopold (Duke of Albany), 68–69  
Leschly, Nick, 177–179, 243, 246  
Lesch–Nyhan syndrome, 156  
Leukemia  
    bone marrow transplants and, 108–109, 110–111  
    chronic myelogenous, 330–331  
    cord blood transplantation for, 122, 123  
    gene therapy and, 160–161, 175, 285  
Levy, Harvey, 17  
Lewy bodies, 318  
Lifton, Richard, 332  
Ligand  
    defined, 241  
    treatment of XLHED with, 247–254  
LINCL (late-infantile neuronal ceroid lipofuscinosis), 286  
Lincoln, Abraham, 185–186  
Lipid metabolism, 47  
Lipid nanoparticles, 297  
Lipoprotein lipase, 289  
Lipoprotein lipase deficiency (LPLD), 179, 289–290  
Liposomes, 156  
*LMO2* gene, 160–161, 285  
Loeys, Robert, 190  
Loeys-Dietz syndrome, 190  
Lofenalac, 9, 15  
*Lorenzo's Oil* (movie), 169, 314

- Losartan, 189–190  
Loss-of-function diseases, 296  
Lotus Tissue Repair, 223–224, 226–228, 311  
Lower, Richard, 55  
Lowman, Gladys, 109  
LPLD (lipoprotein lipase deficiency), 179, 289–290  
LSDs. *See* Lysosomal storage disorders  
Lubs, Herbert, 197, 324  
Lumacaftor, 279  
Lumizyme, 144  
Lung disease, cystic fibrosis as, 267, 269–272  
Lung transplants, 273–274  
Lupski, Jim, 283  
Luria, Salvador, 152, 153  
*LURK2* gene, 320  
L-xylulose, 5  
Lydon, Nick, 330–331  
Lyon, Mary, 48  
Lysosomal storage disorders (LSDs), 19, 117–119, 128  
    blood–brain barrier and, 256  
    chaperone molecules, 256–261  
    Fabry disease, 138–141  
    Gaucher disease, 127–138  
    substrate reduction therapy, 148–150  
Lysosomes, 128
- M**
- Macfarlane, R.G., 74  
Macklin, John, 46  
Macklin, Madge Thurlow, 33, 46  
Macrophages, 130–131, 171–172  
Maguire, Al, 163, 168  
Malaria  
     $\beta$ -thalassemia and, 58  
    G6PD gene mutations and, 2–3  
Malnutrition, cystic fibrosis and, 267–270  
Mannose, 130, 258  
Maple syrup urine disease, 22  
Marfan, Antoine Bernard-Jean, 44, 186–187  
Marfan's law, 186  
Marfan's sign, 186  
Marfan syndrome, 44, 184, 185–190  
    Abraham Lincoln and, 185–186  
    aortic aneurysms, 187–190  
    life expectancy, 188  
    mutations in, 188  
Margus, Brad, 314, 315  
Marks, Joan, 50  
Marks, Paul, 3  
Maroteaux–Lamy syndrome MLS, 111–112  
Martin, J. Purdon, 196–197  
Martin–Bell syndrome, 197  
Mary Lasker Foundation, 215  
Mason, Verne, 38  
Massie, Robert and Suzanne, 71–74  
MAT<sub>21</sub> test, 86–87  
Maternal serum AFP (MSAFP) screening, 25  
Matrix metalloproteases, 189  
Matthews, LeRoy, 271  
McClellan, George, 185  
McCulloch, Ernest, 107  
McKusick, Victor, 34, 42–46, 48, 59, 163, 185–186, 187  
McLaughlin, James, 228–230  
MDA (Muscular Dystrophy Association), 228  
MDC<sub>1</sub>A (merosin-deficient congenital muscular dystrophy), 228–233  
Mead, Margaret, 239  
Mead Johnson (food company), 9, 14–15  
Medicaid, 334  
Medical foods, 9, 16  
Medical genetics  
    genetic counseling, 49–53  
    James Neel and, 34–42, 48  
    rise of, 31–53  
    training programs, 49  
    Victor McKusick and, 34, 42–46, 48  
Meiosis, 193, 199  
Mekinist (trametinib), 311  
Melanin, 7  
Melanoma, metastatic, 331, 333  
Mello, Craig, 296  
Mendel, Gregor, 3  
Mendelian inheritance, 3  
    ABO blood groups and, 57  
    application to human problems, 31–32  
*Mendelian Inheritance in Man (MIM)*  
    (McKusick), 45  
Mental retardation. *See also specific causes*  
    Fragile X syndrome, 88, 196–200, 324  
    microdeletions of chromosomes as cause, 60  
    sterilization laws, 32–33  
Merosin, 229  
Merosin-deficient congenital muscular dystrophy (MDC<sub>1</sub>A), 228–233  
Meryon, Edward, 262  
Metachromatic leukodystrophy (MLD), 123, 181–182  
Metastatic melanoma, 311  
Methotrexate, 117  
Methylprednisone, 117  
Meyers, Abbey, 133  
mGluR5 protein, 201  
Michael J. Fox Foundation (MJFF), 318–320  
Microarray testing, 303–304  
Microdeletions, autism and, 324–328  
Microglial cells, 172, 179  
Migalstat, 260–261  
Miglustat, 149  
The Million Human Genomes Project, 305–306  
Missense mutations, 143  
Mitochondria  
    Friedreich's ataxia and, 190–191, 194, 195  
    genome, 283–284  
Mitochondrial disorder, 283–284

## 382 Index

- MJFF (Michael J. Fox Foundation), 318–320  
MLD (metachromatic leukodystrophy), 123, 181–182  
Molecular biology, 151, 296  
Molecular medicine, 39, 278  
Moloney retrovirus, 160  
Monod, Jacques, 153  
Moore Clinic, 44  
Mootha, Vamsi, 283  
Morgan, Thomas Hunt, 47  
Morpholinos, 264  
Morquio syndrome, 145  
Morris water maze test, 301  
Mosaicism, 305  
Motulsky, Arno, 35, 46–47  
Mouse. *See also* Knockout mice  
    as research animal, 217  
    tabby, 240, 241, 246  
MSAFP (maternal serum AFP) screening, 25  
Mucopolysaccharidosis (MPS) syndromes, 144–145, 147, 150  
Mucopolysaccharidosis type I (MPSI), 144–145, 147  
Mucopolysaccharidosis type II (MPSII), 147  
Mucopolysaccharidosis type IVA (MPS IVA), 145  
Mucopolysaccharidosis type VI (MPS VI), 145  
Mucoviscidosis, 270  
Mucus, in cystic fibrosis, 270–273  
Muenzer, Joseph, 147  
Muller, Hermann J., 33, 47  
Müller, Johannes Peter, 106  
Mullis, Kary, 99  
Murray, Joseph, 108–109  
Muscular atrophy. *See* Spinal muscular atrophy  
Muscular dystrophy  
    Becker, 263, 266  
    congenital (CMD), 231  
    Duchenne (DMD), 83, 184, 228, 262–266, 310  
    MDC1A, 228–233  
Muscular Dystrophy Association (MDA), 228  
Muse, as research animal, 217  
Mutations  
    in  $\beta$ -thalassemia, 58, 60, 95, 155  
    in cancer, 53, 311, 329–330  
    in cardiomyopathies, 332  
    in childhood cerebral  
        adrenoleukodystrophy (CCALD), 119  
    in cystic fibrosis, 271, 274–280  
    in DMD, 262, 264–266  
    in Fabry disease, 139, 260  
    in Fragile X syndrome, 199  
    in Friedreich's ataxia, 193–194  
    gain-of-function, 296  
    in Gaucher disease, 258  
    gene predisposed to error, 101  
    hemoglobin, 39–40, 70  
    in Huntington's disease, 101–102  
    hypomorphs, 332  
    in immune deficiency disorders, 114  
    knock out mice, 217  
    in Leber congenital amaurosis, 291  
    loss-of-function, 296  
    in lysosomal storage disorders (LSDs), 117  
    in Marfan syndrome, 188  
    in metachromatic leukodystrophy (MLD), 181  
    in metastatic melanoma, 331  
    missense, 143  
    Muller's work on, 33, 47–48  
    Neel's work on, 35  
    overcoming, 183–208  
    in Parkinson disease, 319  
    in Pompe disease, 143  
    protective against diabetes development, 333  
    radiation and, 41  
    in rDEB, 211  
    reverse, 263  
    in RPE65 gene, 164–165, 166  
    Rubenstein–Taybi syndrome, 282  
    in sickle cell anemia, 91, 155  
    in spinal muscular atrophy, 204–205  
    spontaneous rate of, 41  
    in Tay–Sachs disease, 89  
    TGF- $\beta$  gene, 190  
    in XLHED, 238, 241, 250, 252  
    in X-linked severe combined immune deficiency (X-SCID), 159  
Myozyme, 143
- ## N
- N*-acetylaspartic acid (NAA), 287  
Nadler, Henry, 84  
Naglazyme, 145  
Naldini, Luigi, 180–181  
Nathwani, Amit, 163  
National Association for Retarded Children, 11  
National Bone Marrow Registry, 113  
National Center for Human Genome Research, NIH, 48–49  
National Down Syndrome Congress, 86  
National Foundation for Ectodermal Dysplasia (NFED), 239, 244–245, 250–251  
National Gaucher Foundation, 135  
National Genetic Diseases Act (NGDA), 98  
National Hemophilia Foundation, 77, 78  
National Institute for Health and Care Excellence (NICE), 280, 334  
National Marrow Donor Program (NMDP), 113–114  
National Organization for Rare Disorders (NORD), 133–134  
National Organ Transplant Act, 113  
National Sickle Cell Anemia Control Act, 92  
National Society of Genetic Counselors, 50  
Natural history studies, 232  
Natural killer cells, 159–160  
Natural selection, 41  
Naughton, Michael, 59  
NDA (New Drug Application), 136  
Necker Hospital (Paris), 116, 121, 159, 256

Neel, James V., 34–42, 48, 57, 59  
Neufeld, Elizabeth, 144–145  
Neural tube defects, 22–29  
    AFP screening, 24–25  
    diagnosis, 24  
    folate supplementation, 25–29  
    incidence of, 23–25, 28  
    screening tests, 51, 52–53  
Neurodegenerative disorder  
    Friedreich's ataxia, 190–196  
    Parkinson disease, 317  
Neurological examination, 172  
Neurotrophic factors, 318  
Neutralizing antibodies, 337  
Newborn screening for cystic  
    fibrosis, 271  
Newborn screening programs, 93  
New Drug Application (NDA), 136  
New York Blood Center, 122  
NFED (National Foundation for Ectodermal  
    Dysplasia), 239, 244–245, 250–251  
NF- $\kappa$ B, 247  
NGDA (National Genetic Diseases Act), 98  
NGLY1 deficiency, 314–315  
NICE (National Institute for Health and Care  
    Excellence), 280, 334  
*Nicholas and Alexandra* (Massie), 73  
Niemann–Pick C (NP-C) disease, 129, 149  
NIPT (noninvasive prenatal testing),  
    304–305, 338–339  
Nixon, Richard, 91–92  
NMDP (National Marrow Donor Program),  
    113–114  
Noel, Walter Clement, 38  
Noninvasive prenatal testing (NIPT), 304–305,  
    338–339  
Nonneuropathic Gaucher disease (type I),  
    118  
Nonpaternity, 42  
Nonprofit patient groups, 313  
NORD (National Organization for Rare Disor-  
    ders), 133–134  
Novartis, 330  
Nowell, Peter, 330  
Nucleus, 106  
Nulls, 232  
Nystagmus, 167

## O

Oakley, Godfrey, 27–28  
Obokata, Haruko, 295  
Odore family, X-linked adrenoleukodystrophy  
    and, 314  
Old Order Amish, 45  
One gene–one enzyme theory, 6  
Online Mendelian Inheritance in Man (OMIM),  
    45, 183  
*On the Origin of Species* (Darwin), 106  
Ontogeny recapitulates phylogeny, 106  
Onze Lieve Vrouwe Gasthuis (OLVG) Hospital,  
    141–142

Opitz, John, 139  
Orchard, Paul, 147  
Organ Procurement and Transplantation Net-  
    work (OPTN), 273–274  
Ornithine transcarbamylase deficiency (OTC),  
    157–158  
Orphan disease companies, valuations of,  
    310–311  
Orphan Drug Act (ODA), 16, 132–133, 313  
Orphan drug status, FDA, 312–313  
Osler, William, 43, 68, 256  
Osteogenesis imperfecta, 184  
Ottenberg, Reuben, 57  
Overheating. *See* Hyperthermia  
Ovists, 105

## P

PAL (phenylalanine ammonia lyase), 21  
Pamaquine, 3  
Pancreas, cystic fibrosis and, 267  
Panhematin, 133  
Paoella, Dave and Lynn, 17–18, 21  
PAPA test, 85  
Paper chromatography, 39  
Papovavirus, 153  
Parker, Harold, 43  
Parkinson, James, 317  
Parkinson disease, 293, 295, 317–320  
    cost of care, 320  
    genes involved, 319–320  
    gene therapy, 318, 319, 320  
    L-dopa for, 318  
    lifetime risk of developing, 317  
Parkinson Disease Foundation, 320  
Parvoviridae, 284  
Paternity, 42  
Patient registry, for Pompe disease, 144  
Pauling, Linus, 39, 97  
PCR (polymerase chain reaction), 99–100  
Pectus excavatum, 187  
Pegylation, 21  
Penrose, Lionel, 84  
Pentosuria, 5  
Peroxisome, 119  
Personalized medicine, 53, 311  
Peutz–Jeghers syndrome, 43  
Pfizer, 180, 333  
PGD (preimplantation genetic diagnosis),  
    98–103  
Phage, 152  
Pharmacogenetics, 47  
Phenylalanine, 15  
    blood level lowered by drugs, 19–20  
    PKU and, 1, 7–11  
Phenylalanine ammonia lyase (PAL), 21  
Phenylalanine hydroxylase, 19  
Phenylketonuria (PKU), 6–22  
    BioMarin drug to treatment of, 145  
    Carol Buck and, 12–13  
    dietary therapy, 8–9, 11, 15–19

384 *Index*

- Phenylketonuria (PKU) (*Continued*)  
  drug therapy, 19–21  
  frequency of diagnosis, 15  
  gene therapy, 21  
  screening for, 7–11, 15, 22  
Phenylpyruvic acid, 6–7, 9  
Phenyltetrazole, 302  
Philadelphia chromosome, 330  
Pinheiro, Marta, 237  
Pippard, Martin, 62  
PKU. *See* Phenylketonuria  
Placebo effect, 55  
Placentas  
  enzymes from, 129–130, 134–135, 137, 257  
  immunoglobulin harvested from, 135  
Plasma, for hemophilia, 70–71, 74–75  
Plasmid, 137  
Pleiotropy, 43–44  
Plomin, Robert, 306  
Pneumonia, 336  
  cystic fibrosis and, 269, 272–273  
  sickle cell anemia and, 65, 66, 93  
Point prevalence, 230–231  
Polymerase chain reaction (PCR), 99–100  
Pompe, Joannes C., 141–142  
Pompe disease, 141–144, 146, 314  
Pompe disease chaperone therapy, 259, 260  
Pool, Ithiel, 75  
Pool, Judith, 75–76  
Posttranslational modifications, 218  
Potentiators, cystic fibrosis, 275  
Precision medicine, 328–333  
Pregnancy  
  amniocentesis risk to, 84  
  sickle cell anemia and, 67  
Pregnancy termination, 28–29, 52, 53  
   $\beta$ -thalassemia, 95–96  
  cystic fibrosis, 274–275  
  Down syndrome and, 84–86  
  ethics and, 339  
  fetal cell analysis and, 87  
  frequency of choosing, 97  
  of non-matching sibling fetus, 122  
  *Roe v. Wade*, 87–88  
  spinal muscular atrophy, 307  
  Tay–Sachs disease, 90–91  
Preimplantation genetic diagnosis (PGD),  
  98–103  
Prejudice, 185  
Premarital screening program, 95  
Prenatal diagnosis/screening, 51–52  
  amniocentesis and, 82–88  
   $\beta$ -thalassemia, 94–96  
  cystic fibrosis, 96, 274–275  
  DNA sequencing, 97  
  ethical debate, 87–88  
  fetal sequencing, 303  
  sickle cell anemia, 93  
  for spinal muscular atrophy, 307  
  for Tay–Sachs disease, 90  
Primaquine, 3  
*Principles of Human Genetics* (textbook), 300  
Prions, 136  
“Product engine” company, 228, 292–293  
Progressive movement, 31–32  
Promoter, triplet expansion in, 199  
Prosenza, 266  
Protein engineering, 79  
Protein replacement therapy, 255. *See also*  
  Enzyme replacement therapy  
  for dystrophic epidermolysis bullosa,  
  220–228  
  for MDC1A, 229–233  
Proteins  
  fusion, 241–242  
  made in Chinese hamster ovary cells, 219  
  median number of amino acids in, 316  
  mending broken, 255–280  
  misfolded, 258–259  
  misshaped in cystic fibrosis, 274–279  
  variation in, 316  
*Proteus vulgaris*, 7  
Prothelia, 229, 233  
*Pseudomonas aeruginosa*, in cystic fibrosis,  
  272  
Puck, Theodore, 218  
Pulmonary edema, 70  
Pupillary light reflex, 167  
Putamen, 319  
Pyeritz, Reed, 188  
Pythagoras, 2
- Q**
- Quality adjusted life year (QALY), 334, 335  
Quantitative trait loci (QTLs), 31  
Quick, A.J., 69
- R**
- Radiation biology, Neel’s work with, 40–41  
Radiation sickness, 107–108  
Rare Diseases Act, 133–134  
Rasputin, 69  
Raymond, Gerald, 172  
Raymond scale, 172  
rDEB. *See* Dystrophic epidermolysis bullosa,  
  recessive  
Reciprocal translocation, 333  
Recombinant DNA Advisory Committee (RAC),  
  157  
Recombinant DNA technology  
  fear of, 151, 154–155  
  history of, 154–156  
Recombinant proteins  
  collagen VII, 220, 223–228  
  human Factor VIII, 78  
Redmond, T. Michael, 164  
Reed, Sheldon, 40, 48  
Reeves, Roger, 301–302  
Regaud, Claude, 107  
Regenerative medicine, 293–295

- Regulatory agencies, approval by, 309–310  
Repligen, 195  
Reproductive risk  
    carrier screening, 89–90  
    genetic counseling, 49  
Reprogramming cells, 294  
Respiratory disease, cystic fibrosis as, 267–272  
Restriction enzymes, 153, 154  
Retinal degenerative disorders, 163–169  
Retinitis pigmentosa, 283  
Retroviruses  
    gene therapy and, 160  
    as vectors, 155–156  
Rett Syndrome Research Trust, 313  
Reverse transcriptase, 153  
Rho vector, 286  
Rh disease, 82  
RhoGAM, 82  
Richter, Melissa, 49–50  
Richter family, XLHED and, 235, 238–239, 243–245  
Rickets, 26  
RNA blocking technology, 264–266  
RNA interference (RNAi), 296–297  
RNA silencing, 296  
Roche, 180, 202  
*Roe v. Wade*, 87–88  
Rogers, Stanfield, 153–154  
Rowley, Janet, 333  
RPE65, 163–169, 291  
Rubinstein–Taybi syndrome, 282  
Rubinstein, Jack Herbert, 282  
Ruddle, Frank, 45
- S**
- Salt concentration, in sweat of cystic fibrosis children, 270  
Saltonstall, Peter, 134  
Sandhoff disease, 148  
Sangamo BioScience, 298  
Sanofi, 146, 292  
Sapropterin hydrochloride, 19  
Sarepta Therapeutics, 264–266  
Sarpong, Helen, 65–67  
Save One Life Foundation, 68, 74  
Savior sibling, 99  
Sawyer, Charles, 331  
SCA. *See* Sickle cell anemia  
Schleiden, Matthias, 105–106  
Schneider, Pascal, 241–242, 245–246  
Schull, William, 35, 40  
Schwann, Theodor, 105–106  
SCID (severe combined immunodeficiency disease), 110, 115  
*Science and the Future* (Haldane), 58  
Scoliosis, 192  
Scott, Robert, 91  
Screening. *See also* Carrier testing; Genetic testing; Prenatal diagnosis/screening for AFP ( $\alpha$ -fetoprotein), 1, 24  
    increasing availability of tests, 22  
    for PKU, 7–11, 15, 22  
    Screening library, 206  
Seaside Therapeutics, 201–202  
Seidman, Christine, 332  
Seidman, John, 332  
Selective abortion, 275. *See also* Pregnancy termination  
Sequencing. *See* DNA sequencing  
Sequenom, 86–87, 304  
Series A investor, 249  
Severe combined immunodeficiency disease (SCID), 110, 115  
Sex-linked disorders. *See* X-linked disorders  
*SH3TC2* gene, 283  
Shapiro, Elsa, 111  
Shaw, Margery, 41–42, 83  
Sheep, cloning, 293  
Sheffield, Charles, 239  
Shire Human Genetic Therapies, 227–228  
Shire Pharmaceuticals, 147, 311  
Shope papillomavirus, 154  
Shriver, Eunice Kennedy, 13–14  
Siblings, conception of HLA-matched, 99  
Sickle cell anemia (SCA), 38–40, 64–67  
    bone marrow transplantation, 125  
    carrier testing, 82, 91–94  
    clinical symptoms, 65–66  
    cord blood transplantation, 124–125  
    current research, 67  
    gene therapy, 174–175  
    life expectancy, 67, 91  
    mutations in, 155  
    testing laws, 92  
Sideramines, 62  
Siemens, Hermann Werner, 209–210, 236–237  
Silvestroni, Ezio, 37  
Single-gene disorders, 255. *See also specific disorders*  
    number of, 281  
    number of treatable, 281  
Skin disorders  
    dystrophic epidermolysis bullosa, 209–228  
    X-linked hypohidrotic ectodermal dysplasia (XLHED), 235–254  
Skin grafts, 108  
Slanetz, Alfred, 174–175, 177  
Smile, Duchenne, 261–262  
SMN (survival motor neuron) genes, 204–208  
Snyder, Laurence, 33  
Snyder, Sheridan, 132  
Social policy questions, genetic testing and, 98  
Sodium benzoate, 157  
Sodium phenylbutyrate, 206  
Somatic cell hybridization, 45  
Southard, Elmer Ernest, 287  
Spark Therapeutics, 163, 169, 180, 292, 311  
Spencer, Warren, 35  
Spermatists, 105  
Spermatogenesis, 107  
Spina bifida, 23, 28–29

## 386 Index

- Spinal muscular atrophy, 203–208  
DNA testing, 205  
drug discovery research, 205–207  
history of, 203–204  
incidence of, 204  
mutation in SMN genes, 204–205  
Spinal muscular atrophy type 1 (SMA<sub>1</sub>), 185,  
204–205, 292, 306–307  
Spleen, enlargement of, 63, 256–257  
Splenic anemia, 256–257  
Spontaneous generation, 106  
Spontaneous mutation rate, 41  
STAP cells, 295  
Steele, Mark, 83  
Steinberg, Martin, 65  
Stem cells, 105–125  
bone marrow transplants, 110–120  
as childhood cerebral  
adrenoleukodystrophy (CCALD) ther-  
apy, 119–120  
cord blood, 120–125  
gene therapy, 160  
history, 105–110  
induced pluripotent stem cells (iPSCs),  
294–295  
sickle cell anemia and, 67  
Stem cell transplant  
allogenic, 173  
for childhood cerebral adrenoleukodystro-  
phy (CCALD), 171–173  
for rDEB, 224  
Stent, Gunther, 151  
Sterilization laws, 32–33  
Stern, Curt, 35  
Stokowski, Leopold, 151  
Storage Disease Collaborative Study  
Group, 119  
Storage disorders. *See also* lysosomal storage  
disorders  
BMT for, 111–112  
LINCL, 286  
metachromatic leukodystrophy (MLD),  
181–182  
Pompe disease, 141–148  
Stricos, Andrew and Amanda, 102–103  
STRIVE study, 277  
Substantia nigra, 318  
Substrate reduction, 148–150  
Summerton, James, 264  
Supplements, folate, 26–29  
SV40 virus, 153, 154  
Sweat glands, in XLHED, 236, 238–240, 242,  
245, 251  
Sweat test, 270–271  
Synageva, 310  
Syncytiotrophoblasts, 305
- T**  
Tafinlar (dabrafenib), 311  
TALENs (transcription-activator-like effector  
nucleases), 297, 298
- Targeted abortion, 88. *See also* Pregnancy  
termination  
Tax credits, 133  
Taybi, Hooshang, 282  
Tay–Sachs disease, 89–91, 129  
carrier testing, 82  
incidence of, 281  
substrate reduction therapy, 148  
T cells, 114, 115–117, 120, 159–160  
Teeth, lack in XLHED, 235–236, 238–240, 242,  
244–245  
Temin, Howard, 153  
Termeer, Henri, 131–132, 134–136, 142–146,  
258  
Testing. *See* Genetic testing; Prenatal diagno-  
sis/screening  
Tetrahydrobiopterin (BH<sub>4</sub>), 19  
TGF- $\beta$  (transforming growth factor-beta), 188–  
190  
Thalassemia, 36–38. *See also*  $\beta$ -thalassemia  
life expectancy with, 63–64  
life of patients with, 64  
transfusions for, 60–64  
*The Thalassemia Syndromes* (Weatherall), 60  
Thapa, Jaspir, 59, 64  
Third Rock Ventures (TRV)  
AAV therapy company, 292, 312  
childhood cerebral adrenoleukodystrophy  
(CCALD), 174, 177  
International Rare Disease Day, 225  
merosin-deficient congenital  
muscular dystrophy (MDC1A), 228  
rDEB and, 215, 221, 224–225  
X-linked hypohidrotic ectodermal dysplasia  
(XLHED), 243, 247, 249  
Thomas, E. Donnell, 108–109, 113  
Thomson, James, 293–294  
Thrasher, Adrian, 160  
Thurman, John, 236  
Till, James, 107  
Tissue plasminogen activator (TPA), 219  
TMLHE (trimethyllysine hydroxylase epsilon)  
deficiency, 327–328  
TNF ligands, 241  
Tobacco mosaic virus (TMV), 153  
Tomé, F.M., 229  
Tonsils, 109  
TopoTarget, 243  
Touraine, Albert, 237  
Tourette's syndrome, 133  
TPA (tissue plasminogen activator), 219  
TRAFFIC trial, 279  
Training School (Vineland, New Jersey), 12, 13  
Transabdominal chorionic villus biopsy, 95  
Transcription, exon-skipping and, 264–266  
Transcription-activator-like effector nucleases  
(TALENs), 297, 298  
Transfusions, 37–38  
frequency in United States, 57  
fresh frozen plasma (FFP), for hemophilia,  
70–71, 74–75



for hemophilia, 70, 72  
history of, 55–57  
for sickle cell anemia, 67  
for thalassemia, 57, 60–64, 94  
Translocation, reciprocal, 330  
Transplantation  
  bone marrow (see Bone marrow transplant)  
  history of, 108  
  HLA system and, 109–110  
  mortality risk of, 121  
  stem cell, 171–173, 224  
TRANSPORT trial, 279  
Transthyretin amyloidosis, 297  
Treatable population, 232  
*Treatise of Diseases of Children* (Marfan), 186  
Trimethyllysine hydroxylase epsilon (TMLHE)  
  deficiency, 327–328  
Triplet repeats, 102  
  Fragile X syndrome, 199–200  
  Friedreich's ataxia, 193  
Trisomies, 299–300, 304–305. *See also* Down  
  syndrome  
Trisomy 13, 299  
Trisomy 18, 299  
Trisomy 21. *See* Down syndrome  
Tropism, 161, 289  
TRV. *See* Third Rock Ventures  
Trypsinogen, 270–271  
Tsien, Roger, 275  
TTP-1 enzyme, 286  
Tuberculosis, 186, 335  
Tumor genome analysis, 331  
Tumor profiling, 331–332  
Tunney, John, 92  
23andMe, 319  
Twin studies, 236  
Typhoid fever, 186  
Tyrosine, 4–5, 7, 22  
Tyrosine kinases, 330–331  
Tyrosinemia, 22

## U

Uitto, Jouni, 216  
Ultragenyx, 311  
Ultrasound, Down syndrome diagnosis and, 85  
UniQure, 179, 290  
University of Minnesota, bone marrow  
  transplantation and, 109–110, 114, 116,  
  119–120, 123, 147, 171, 173, 224  
Urea cycle, 148

## V

Valentine, Bill, 37  
Valproic acid, 206  
*The Variation of Animals and Plants* (Darwin),  
  236  
Varmus, Harold, 157  
Vectors. *See* Viral vectors  
Vella, Frank, 59  
Vellucci, Alfred, 155

Vemurafenib, 331, 333  
Venture capital, 163, 174, 180, 245  
Venture philanthropy, 278–279  
Verinata, 86  
Verma, Inder, 180  
Vertex Pharmaceuticals, 276–280  
Very-long-chain fatty acids (VLCFAs), 119  
Vichinsky, Elliott, 64  
Victoria (Queen of England), 68  
Viral vectors, 155–156, 160–163, 165, 168,  
  174–176, 179–181, 196  
  adeno-associated viral (AAV) vectors, 21,  
  284–293, 312, 337  
  adenovirus, 156, 158  
  future challenges, 336–337  
  lentiviral vectors, 67, 174–176, 179, 181, 285  
  retroviruses, 155–156  
  tropism, 289  
Virchow, Rudolf, 106  
Virginia Center for Reproductive Medicine, 100  
Virtual company, 248  
Vitalism, 106  
Vitamin A, role in vision, 164  
Vitamin B<sub>12</sub> deficiency, 27  
Vitamin D, in milk, 26  
Vivigen, 137  
Voyager Therapeutics Corporation, 232,  
  292–293, 312  
VX-770, 276

## W

Wald, George, 164  
Wald, Nicholas, 24  
Walter E. Fernald State School, 1, 14, 198, 282  
Wapner, Ron, 303  
Warner, Robert, 10  
WAS (Wiskott–Aldrich syndrome), 115  
Watson, James, 48, 151, 276  
Weatherall, David, 59–60, 64  
Wedderburn, W., 236  
Werdnig, Guido, 203  
Werdnig–Hoffman disease, 204  
Weve, H.J.M., 44  
Wexler, Nancy, 101  
Whipple, George, 36  
Whitesides, George M., 132  
Whole exome sequencing, 283, 325  
Whole genome sequencing, 305–306, 314  
Wilmot, Ian, 293  
Wilsey family, NGLY1 deficiency and, 314–315  
Wilson, Edmund, 107  
Wilson, James, 79, 157–159, 285  
Wiskott–Aldrich syndrome (WAS), 115  
Wojcicki, Anne, 319  
Wolff, Caspar Friedrich, 105  
Wolman, Irving, 61  
Woodley, David, 215–216, 219–220  
Woolf, Louis, 9  
Wren, Christopher, 55  
Wright, Fraser, 163  
Wrongful birth lawsuits, 84

**388**     *Index*

**X**

- Xavante people, 41
- X chromosomes
  - inactivation, 3, 48, 140, 302
  - microdeletion associated with autism on, 327
- XIST* gene, 302
- X-linked adrenoleukodystrophy (XLALD), 169–170, 314. *See also* Childhood cerebral adrenoleukodystrophy (CCALD)
- X-linked disorders. *See also specific disorders*
  - carnitine deficiency microdeletion, 327
  - childhood cerebral adrenoleukodystrophy (CCALD), 119
  - Duchenne muscular dystrophy, 228, 261–266
  - Fabry disease, 139–141, 260
  - Fragile X syndrome, 88
  - G6PD deficiency, 2–3
  - gender identification by amniocentesis, 82–83
  - hemophilia, 68
  - hypophosphatasia, 311
  - ornithine transcarbamylase deficiency (OTC), 157–158
  - Wiskott–Aldrich syndrome (WAS), 115
- X-linked adrenoleukodystrophy (XLALD), 169–170, 314
- X-linked hypohidrotic ectodermal dysplasia (XLHED), 235–254
- X-linked severe combined immune deficiency (X-SCID), 159–161, 175
- X-linked hypohidrotic ectodermal dysplasia (XLHED), 235–254
  - carriers, identification of, 248, 250–252
  - clinical features of, 235–238
  - dog model, 239–242
  - early history of, 236–237
  - EDA protein therapy, 242–243, 246
  - incidence/prevalence, 248–250
  - ligand for treatment of, 247–254
  - mouse model, 240, 241
  - NFED advocacy group, 239, 244–245, 250–251
  - Richter family experience with, 235, 238–239, 243–245
  - skin disorders, 235–254
- X-linked hypophosphatasia, 311
- X-linked severe combined immune deficiency (X-SCID), 159–161, 175
- Xylulose, 5

**Y**

- Yamanaka, Shinya, 294
- Yanomami people, 41
- Y chromosome, 99

**Z**

- Zavesca, 149
- Zelboraf, 331, 333
- Zinc finger nucleases (ZFNs), 297–298
- ZnT8* gene, 333
- Zonana, Jon, 238, 240
- Zuckerberg, Mark, 97
- Zuelzer, Wolf, 38
- Zumwalt, E.R., 113